<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="5" ids="16709">Pyridoxine</z:chebi>, or <z:chebi fb="14" ids="27306">vitamin B6</z:chebi>, is commonly used to treat acquired idiopathic sideroblastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (AISA, including refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with ring sideroblasts), but the efficacy of this therapy in an unselected AISA population (i.e. patients without confirmed ALAS2 or other <z:chebi fb="5" ids="16709">pyridoxine</z:chebi>-responsive germline mutations) has not been established </plain></SENT>
<SENT sid="1" pm="."><plain>We reviewed clinical data from 231 patients with AISA and found that 42% of 203 evaluable patients had been treated with <z:chebi fb="5" ids="16709">pyridoxine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Only 6.8% of <z:chebi fb="5" ids="16709">pyridoxine</z:chebi>-treated patients experienced a <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> improvement (â‰¥ 1.5 g/dL) meeting 2006 International Working Group for <z:hpo ids='HP_0002863'>Myelodysplastic Syndromes</z:hpo> standardised response criteria </plain></SENT>
<SENT sid="3" pm="."><plain>As some patients received combination therapy with erythropoietin or other agents, improvement could be attributed to <z:chebi fb="5" ids="16709">pyridoxine</z:chebi> monotherapy in only one patient (1.4%) </plain></SENT>
<SENT sid="4" pm="."><plain>Smaller, less meaningful increments in <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> levels of 0.5 g/dL were observed in 13.5% of patients </plain></SENT>
<SENT sid="5" pm="."><plain>Response to therapy did not correlate with International Prognostic Scoring System (IPSS) risk group or multilineage vs unilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>New symptomatic <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> was noted in 2.3% of patients treated with <z:chebi fb="5" ids="16709">pyridoxine</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>In this large series of unselected patients with sideroblastic <z:hpo ids='HP_0001903'>anaemia</z:hpo>, <z:chebi fb="5" ids="16709">pyridoxine</z:chebi> therapy was ineffective and was associated with a risk of adverse effects </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="5" ids="16709">Pyridoxine</z:chebi> therapy should be reserved for patients with known or suspected <z:chebi fb="5" ids="16709">pyridoxine</z:chebi>-responsive mutations </plain></SENT>
</text></document>